ArticlePharmaceutical research2019
Sugar Modification Enhances Cytotoxic Activity of PAMAM-Doxorubicin Conjugate in Glucose-Deprived MCF-7 Cells - Possible Role of GLUT1 Transporter.
Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 54 citations in OpenAlex.
- Breast cancer: taxonomy, distribution analysis, risk factors, predictive biomarkers, and modern treatment method.Apoptosis : an international journal on programmed cell death · 2026Review
- Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response.Cancer biology & therapy · 2024Review
- The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer.Biomedicines · 2023Review
- Functionalized Mesoporous Silica as Doxorubicin Carriers and Cytotoxicity Boosters.Nanomaterials (Basel, Switzerland) · 2022Article
- Application of Dendrimers in Anticancer Diagnostics and Therapy.Molecules (Basel, Switzerland) · 2022Review
- Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.Frontiers in immunology · 2022Review
- Design and Characterization of Maltoheptaose-Molecules (Basel, Switzerland) · 2021Article
- Glycosylation of PAMAM dendrimers significantly improves tumor macrophage targeting and specificity in glioblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Chitosan-Based Glycolipid Conjugated siRNA Delivery System for Improving Radiosensitivity of Laryngocarcinoma.Polymers · 2021Article
- Lysine-mediated hydroxyethyl starch-10-hydroxy camptothecin micelles for the treatment of liver cancer.Drug delivery · 2020Article
- Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery.Cancers · 2020Review
- Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine.Cancers · 2020Review
- Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art.Pharmaceutics · 2020Review
- Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeIn order to overcome the obstacles and side effects of classical chemotherapy, numerous studies have been performed to develop the treatment based on targeted transport of active compounds directly to the site of action. Since tumor cells are featured with intensified glucose metabolism, we set out to develop innovative, glucose-modified PAMAM dendrimer for the delivery of doxorubicin to breast cancer cells.
methodsPAMAM-dox-glc conjugate was synthesized and characterized by
resultsWe showed that PAMAM-dox-glc conjugate exhibits pH-dependent drug release and increased cytotoxic activity compared to free drug in cells cultured in medium without glucose. Further, we proved that these cells overexpress transporters of GLUT family. The toxic effect of conjugate was eliminated by the application of specific GLUT1 inhibitors.
conclusionOur findings revealed that the glucose moiety plays a crucial role in the recognition of cells with high expression of GLUT receptors. By selectively blocking GLUT1 transporter we showed its importance for the cytotoxic activity of PAMAM-dox-glc conjugate. These results suggest that PAMAM-glucose formulations may constitute an efficient platform for the specific delivery of anticancer drugs to tumor cells overexpressing transporters of GLUT family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.